Chardan Capital analyst Keay Nakae reiterated a Buy rating on BiomX (PHGE - Research Report) today and set a price target of $6.00. The company's shares closed yesterday at $0.73.Nakae covers the Healthcare sector, focusing on stocks such as BiomX, Arbutus Biopharma, and Synlogic. According to TipRanks, Nakae has an average return of 7.7% and a 41.50% success rate on recommended stocks. Currently, the analyst consensus on BiomX is a Strong Buy with an average price target of $8.00, implying a 995.89% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.
https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-biomx-phge?utm_source=advfn.com&utm_medium=referral